Circulating tumor DNA as a preoperative marker of recurrence in patients with peritoneal metastases of colorectal cancer: A clinical feasibility study
| Autor: | Geert Kazemier, Daniëlle A.M. Heideman, Jurriaan B. Tuynman, Nicole C.T. van Grieken, Jamie J. Beagan, Sander Bach, Paul P. Eijk, D. Michiel Pegtel, Nina R. Sluiter, Stijn L. Vlek, Bauke Ylstra, Miranda Kusters |
|---|---|
| Přispěvatelé: | Pathology, Surgery, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, Amsterdam Gastroenterology Endocrinology Metabolism, AGEM - Re-generation and cancer of the digestive system |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty Colorectal cancer lcsh:Medicine colorectal cancer Article droplet digital PCR 03 medical and health sciences 0302 clinical medicine Internal medicine Medicine Digital polymerase chain reaction In patient Liquid biopsy CRS-HIPEC 030304 developmental biology circulating tumor DNA 0303 health sciences liquid biopsy business.industry Systemic chemotherapy lcsh:R General Medicine medicine.disease Highly sensitive peritoneal metastases Circulating tumor DNA 030220 oncology & carcinogenesis Hyperthermic intraperitoneal chemotherapy business |
| Zdroj: | Beagan, J J, Sluiter, N R, Bach, S, Eijk, P P, Vlek, S L, Heideman, D A M, Kusters, M, Pegtel, D M, Kazemier, G, van Grieken, N C T, Ylstra, B & Tuynman, J B 2020, ' Circulating tumor DNA as a preoperative marker of recurrence in patients with peritoneal metastases of colorectal cancer: A clinical feasibility study ', Journal of Clinical Medicine, vol. 9, no. 6, 1738 . https://doi.org/10.3390/jcm9061738, https://doi.org/10.3390/jcm9061738 Journal of Clinical Medicine, Vol 9, Iss 1738, p 1738 (2020) Journal of Clinical Medicine, 9(6):1738 Journal of Clinical Medicine Volume 9 Issue 6 |
| ISSN: | 2077-0383 |
| DOI: | 10.3390/jcm9061738 |
| Popis: | Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) may be curative for colorectal cancer patients with peritoneal metastases (PMs) but it has a high rate of morbidity. Accurate preoperative patient selection is therefore imperative, but is constrained by the limitations of current imaging techniques. In this pilot study, we explored the feasibility of circulating tumor (ct) DNA analysis to select patients for CRS-HIPEC. Thirty patients eligible for CRS-HIPEC provided blood samples preoperatively and during follow-up if the procedure was completed. Targeted Next-Generation Sequencing (NGS) of DNA from PMs was used to identify bespoke mutations that were subsequently tested in corresponding plasma cell-free (cf) DNA samples using droplet digital (dd) PCR. CtDNA was detected preoperatively in cfDNA samples from 33% of patients and was associated with a reduced disease-free survival (DFS) after CRS-HIPEC (median 6.0 months vs median not reached, p = 0.016). This association could indicate the presence of undiagnosed systemic metastases or an increased metastatic potential of the tumors. We demonstrate the feasibility of ctDNA to serve as a preoperative marker of recurrence in patients with PMs of colorectal cancer using a highly sensitive technique. A more appropriate treatment for patients with preoperative ctDNA detection may be systemic chemotherapy in addition to, or instead of, CRS-HIPEC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|